Detecting cancer at an early stage is essential to maximize the chances of recovery.
But some tumors remain discreet for a long time.
If there are no symptoms, where do you look?
What signal are we looking for?
For several years, work on liquid biopsy has attempted to meet this challenge.
The principle: search in a sample of bodily fluid (blood, urine) for traces of biomarkers left by the tumor, and analyze them to trace back to the beginning cancer.
Most of the technologies in development rely on finding tumor DNA in the bloodstream, but a Swedish team has just published in the
Pnas
(Reports of the American Academy of Sciences) promising results targeting proteins based on sugars, glycosaminoglycans or glycans.
Previous research had shown that their production was disrupted in cancer.
To demonstrate the interest of this new technology, the team of Francesco Gatto…
This article is for subscribers only.
You have 79% left to discover.
Pushing back the limits of science is also freedom.
Keep reading your article for €0.99 for the first month
I ENJOY IT
Already subscribed?
Login
